You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An Intraoperative Guidance Platform for Radio Frequency Ablation

    SBC: NE SCIENTIFIC LLC            Topic: 102

    Project Summary: The objective of this proposed research program is to develop a platform for planning and guidance during Radio Frequency Ablation (RFA). RFA is a thermally mediated ablation technique, where an applicator carrying one electrode is inserted into tumors percutaneously (or via laparoscopy, or open surgical approaches). Radio Frequency (RF) energy is applied, denaturating and coagula ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing

    SBC: Mattek Corporation            Topic: NIEHS

    Results of Phase II research indicate that formal validation of the EpiAirwayin vitro human bronchial tissue model for predicting toxicity of inhaled chemicals is an attainable goalThe proposed Phase IIB cooperative agreement project is intended to realize this goal by conducting formal ring trial validation studies that will be submitted to regulatory agencies and the Organization for Economic Co ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Novel non-invasive antigen detection assay for the diagnosis of active visceral leishmaniasis and to monitor the therapy efficacy of this disease

    SBC: DETECTOGEN INC.            Topic: NIAID

    ABSTRACTThe overall goal of this Phase II project is to validate novel leishmanial protein biomarkers for development of a non invasive urine based assay to diagnose active visceral leishmaniasisVLand to monitor the therapeutic efficacy of this serious diseaseVL is endemic incountriesaffectspeople a year and kills more thanof them children under ageVLalso known as kala azaris caused by parasites o ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. OnTrack> An Online Role-Playing Game

    SBC: C4 Innovations, LLC            Topic: 104

    Project Summary First episode psychosis is a serious mental health condition that affects youth and young adultsoften between the ages ofandThe illness is marked by hallucinationsdelusionswithdrawalpoor organization skillsand diminished cognitive and social functioningRecent research has demonstrated that programs designed to treat people experiencing early psychosis can reduce hospitalizationdecr ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Evidence-Based Pain Intervention for Veterans: Leveraging Mobile and Social Media

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NCCIH

    Chronic musculoskeletal pain creates a significant public health burden, and Veterans are disproportionately affected. The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), all three conditions (Post-deployment Multi-symptom Disorder (PMD), and other multi-symptom syndromes can complicate and reduce the effectiveness of pain treatment. Furthermore, the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings

    SBC: ALDATU BIOSCIENCES INC            Topic: R

    TheWHO guidelines recommend anti retroviral therapyARTfor all HIV infected peopleand massive efforts to expand ART access will result in andgtM adults and andgtM children on ART byat a cost of almost US$BConsequentlythe number of patients prescribed alternativeprotease inhibitorPIbased ART following failure of first line regimens will also increaseStudies of patients on PI based ART in resource li ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A novel immunotolerizing therapy for autoimmune vitiligo

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NIAMS

    Radikal TherapeuticsRTXis developing a pioneering therapy to restore immunotolerance and arrest progressive depigmentation in vitiligoAt our partnering institutionLoyola University Chicagoa variant to inducible Heat Shock Proteinwas developed with remarkable potential for the prevention and treatment of autoimmune vitiligoCarrying only a single amino acid modification to the proteinthis variant HS ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development of PAR2 Pepducins as a Novel NASH Treatment

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: 300

    Non alcoholic steatohepatitisNASHis characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosiscirrhosis and high mortality ratesNASH is frequently associated with other common metabolic abnormalitiessuch as insulin resistance and visceral obesityLiver transplantation is currently the only effective therapeutic approach for seve ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Fracture Risk Assessment Software for Skeletal Metastasis

    SBC: BIOSENSICS LLC            Topic: NIAMS

    PROJECT SUMMARY ABSTRACT The skeleton is the third most common site of metastatic cancerand nearly half of all cancers metastasize to boneAs a result of new and aggressive treatments cancer patients are living longerbut at sites of skeletal metastasis fractures occur inof affected bones after minimal traumaThis significantly impacts patient functioning and quality of lifeWhile much has been learne ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Commercializing Praedicare Dx TM platform for guiding cancer treatments

    SBC: Eutropics Pharmaceuticals, Inc.            Topic: 102

    Abstract The Eutropics PraediCare Dxis an emerging clinical diagnostic assay that will be used to predict patient response to specific chemotherapiesUnlike existing assaysPraediCare Dxpredicts response to specific chemotherapies by direct evaluation of cancer cells potential to enter into an apoptotic state following exposure to therapyPraediCare Dxhas the potential to provide actionable data for ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government